Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies
Status:
Unknown status
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
This is an open mono-centric prospective non-randomized study in patients with metastatic
melanoma treated with Anti-PD1 monoclonal antibodies (Nivolumab). The aim of the study is to
identify the immune cells modulations differences between patients who present a complete,
partial or stable response and patients who have non-response to the therapy in order to
establish an improving response rate strategy.